New hope for kids with rare bone disease as experimental drug enters final testing
NCT ID NCT06079372
First seen Nov 14, 2025 · Last updated May 16, 2026 · Updated 21 times
Summary
This study tests a new medicine called ALXN1850 in children aged 2 to 12 who have hypophosphatasia (HPP), a rare genetic condition that weakens bones. All participants have already been on the current treatment, asfotase alfa, for at least 6 months. The goal is to see if ALXN1850 is safer and works as well or better at controlling the disease. About 43 children will take part, and they will receive either the new or the current drug by injection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPOPHOSPHATASIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Hartford, Connecticut, 06106, United States
-
Research Site
Baltimore, Maryland, 21287, United States
-
Research Site
Minneapolis, Minnesota, 55455, United States
-
Research Site
Kansas City, Missouri, 64108, United States
-
Research Site
Durham, North Carolina, 27705, United States
-
Research Site
Nashville, Tennessee, 37212, United States
-
Research Site
Mar del Plata, B7600, Argentina
-
Research Site
South Brisbane, 4101, Australia
-
Research Site
Ottawa, Ontario, K1H 8L1, Canada
-
Research Site
Bunkyō City, 113-8431, Japan
-
Research Site
Minatoku, 105-8471, Japan
-
Research Site
Suita-shi, 565-0871, Japan
-
Research Site
Yonago-shi, 683-8504, Japan
-
Research Site
Altındağ, 06230, Turkey (Türkiye)
-
Research Site
Ankara, 06560, Turkey (Türkiye)
-
Research Site
Edirne, 22030, Turkey (Türkiye)
-
Research Site
Erzurum, 25240, Turkey (Türkiye)
-
Research Site
Istanbul, 34899, Turkey (Türkiye)
-
Research Site
Birmingham, B4 6NH, United Kingdom
-
Research Site
Manchester, United Kingdom
-
Research Site
Sheffield, S10 2TH, United Kingdom
Conditions
Explore the condition pages connected to this study.